BIOMARKER:

B2M-H

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

B2M-H	Chronic Lymphocytic Leukemia	B2M-H	Chronic Lymphocytic Leukemia	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
B2M-H	Chronic Lymphocytic Leukemia	B2M-H	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: C3 – Early Trials venetoclax + ibrutinib Sensitive : C3	venetoclax + ibrutinib Sensitive: C3 – Early Trials venetoclax + ibrutinib Sensitive : C3
B2M-H	Multiple Myeloma	B2M-H	Multiple Myeloma	Immunomodulator Resistant: C3 – Early Trials Immunomodulator Resistant : C3	Immunomodulator Resistant: C3 – Early Trials Immunomodulator Resistant : C3
B2M-H	Multiple Myeloma	B2M-H	Multiple Myeloma	Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials Proteasome inhibitor + Immunomodulator Resistant : C3	Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials Proteasome inhibitor + Immunomodulator Resistant : C3
B2M-H	Multiple Myeloma	B2M-H	Multiple Myeloma	Proteasome inhibitor Resistant: C3 – Early Trials Proteasome inhibitor Resistant : C3	Proteasome inhibitor Resistant: C3 – Early Trials Proteasome inhibitor Resistant : C3
B2M-H	Squamous Cell Carcinoma of Head and Neck	B2M-H	Squamous Cell Carcinoma of Head and Neck	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3